Spanish-Portuguese Thrombotic Thrombocytopenic Purpura Registry

TTP is a rare life-threatening haematological disease characterised by thrombotic microangiopathy (TMA) with an average annual prevalence of approximately 10 cases/million people worldwide and an annual incidence between 1.5 and 6.0 cases per million according to different studies conducted in France, the United States and in the United Kingdom. In Spain the incidence is 2,67 cases / million population per year.

Acute TTP episodes cause sequelae like vascular disease or kidney damage along with other symptoms more subtle like small neurocognitive deficits and myocardial infarction.

Thus, prompt resolution of acute episodes along with a better understanding of the cardiac abnormalities may allow to prevent further complications, to develop targeted rehabilitation techniques for TTP patients and to improve their quality of life.

This project will collect a big database capable of providing better answers to questions related with treatment efficacy, associated morbidity and mortality, and the possible neurocognitive and cardiac sequelae derived from relapses and acute episodes. Additionally, this project will be linked to obtaining biological samples for a serum and DNA library from patients with TTP.

Patients will be recruited by medical researchers specialized in haematology or by other investigators specialized in thrombotic microangiopathies disease management. This recruitment will be performed in a competitive manner. The collection period will be at least 3 years with the possibility of extending it.

REPTT aims to evaluate new scores and prognostic factors of morbidity and mortality in TTP patients.

The final aim is to establish guidelines and recommendation to improve the global management, diagnosis and treatment of patients with TTP in real-life.

• Clinical response to treatment rate [Срок оценки: Throughout the study period, approximately 3 years per patient]
• TTP Clinical remission rate [Срок оценки: Throughout the study period, approximately 3 years per patient]
• TTP Exacerbation rate [Срок оценки: Throughout the study period, approximately 3 years per patient]
• TTP Relapse rate [Срок оценки: Throughout the study period, approximately 3 years per patient]
• Refractory TTP rate [Срок оценки: Throughout the study period, approximately 3 years per patient]
• Time-to-response (TTR) [Срок оценки: Throughout the study period, approximately 3 years per patient]
• Duration of response (DoR) [Срок оценки: Throughout the study period, approximately 3 years per patient]
• Relapse-free survival (RFS) [Срок оценки: Throughout the study period, approximately 3 years per patient]
• Overall survival (OS) [Срок оценки: Throughout the study period, approximately 3 years per patient]
• Frequency of serious adverse events (SAEs) [Срок оценки: Throughout the study period, approximately 3 years per patient]
• Rate of complications associated with plasma exchange treatment [Срок оценки: Throughout the study period, approximately 3 years per patient]
• Frequency of complications associated with plasma exchange treatment [Срок оценки: Throughout the study period, approximately 3 years per patient]